Activation of mammalian target of rapamycin (mTOR) signaling occurs in a wide variety of
human tumors and can lead to increased susceptibility to mTOR inhibitors. Temsirolimus, a
novel analog of rapamycin, has shown promising preclinical and early clinical anti-tumor
activity in various solid and hematologic tumor types, either alone or in combination with
chemotherapy or other targeted agents. Randomized phase III trials have already
demonstrated significant clinical benefits of treatment with single-agent temsirolimus in …